OncoMatch/Clinical Trials/NCT06855524
Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer
Official title: MC231007 Fucoidan For Patients With Chemotherapy-Related Fatigue: A Double-Blind, Randomized, Placebo-Controlled Pilot Study
Is NCT06855524 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies non-drug interventions for malignant digestive system neoplasm.
This phase II trial tests how well fucoidan works in preventing chemotherapy-related fatigue compared to a placebo in patients with gastrointestinal (GI), gynecological (GYN), breast, or lung cancer. Fatigue poses a burden in patients with malignancies undergoing systemic chemotherapy. Fucoidan is a dietary supplement made of complex sugar that contain sulfate groups attached to their sugar units (sulfated polysaccharide) which found in brown seaweed. It is thought to have anti-inflammatory, anti-viral, anti-thrombotic, anti-diabetic, and anti-tumor effects in pre-clinical models. Giving fucoidan may be effective in preventing chemotherapy-related fatigue in patients with GI, GYN, breast, or lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to registration)
Kidney function
Creatinine ≤ 1.5 x upper normal limit (UNL) OR calculated creatinine clearance ≥ 50 ml/min using the Cockcroft-Gault (obtained ≤ 30 days prior to registration)
Liver function
ALT and AST ≤ 1.5 x UNL; ≤ 5 x ULN for patients with liver involvement (obtained ≤ 30 days prior to registration)
Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to registration); Creatinine ≤ 1.5 x upper normal limit (UNL) OR calculated creatinine clearance ≥ 50 ml/min using the Cockcroft-Gault (obtained ≤ 30 days prior to registration); ALT and AST ≤ 1.5 x UNL; ≤ 5 x ULN for patients with liver involvement (obtained ≤ 30 days prior to registration)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06855524 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages